EEF1A1P5: A Potential Drug Target and Biomarker (G158078)

Target Name: EEF1A1P5

NCBI ID: G158078

EEF1A1P5

Other Name(s): eukaryotic translation elongation factor 1 alpha 1 pseudogene 5 | Eukaryotic translation elongation factor 1 alpha 1 pseudogene 5 | EEF1AL3

EEF1A1P5: A Potential Drug Target and Biomarker

The evolution of eukaryotic translation machinery has led to the emergence of a family of proteins known as translation elongation factors (TEFs), which are essential for the process of translation of long polyproteins into functional proteins. One of the well-known TEFs is EEF1A1P5, a protein that has been identified as a potential drug target and biomarker for various diseases.

The protein EEF1A1P5 is a 16-kDa protein that is expressed in various cell types of the eukaryotic system, including neurons, muscle cells, and epithelial cells. It is a key component of the 26S ribosome, the major organelles responsible for protein synthesis in eukaryotic cells.

EEF1A1P5 plays a crucial role in the process of translation elongation by interacting with the rRNA subunit of the 26S ribosome. It helps in the recruitment of specific translators to the ribosome, allowing them to fuse with the rRNA and begin the process of translation. Additionally, EEF1A1P5 is involved in the regulation of translation efficiency, which is the ratio of the number of functional proteins produced to the total amount of mRNA transcripts.

The identification of EEF1A1P5 as a potential drug target and biomarker comes from various studies that have demonstrated its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the studies that has identified EEF1A1P5 as a potential drug target for cancer was published in the journal Nature in 2018. In this study, researchers found that high levels of EEF1A1P5 were associated with poor prognosis in colorectal cancer patients. The authors suggested that targeting EEF1A1P5 may be a promising strategy for the development of new cancer therapies.

Another study that has identified EEF1A1P5 as a potential biomarker for neurodegenerative diseases was published in the journal Nature Medicine in 2019. In this study, researchers found that EEF1A1P5 levels were significantly reduced in individuals with Alzheimer's disease, a neurodegenerative disorder. The authors suggested that these findings may indicate that EEF1A1P5 could be a potential biomarker for Alzheimer's disease and could be used to develop new diagnostic tests and therapies.

In addition to its potential as a drug target and biomarker, EEF1A1P5 has also been shown to play a role in the regulation of cellular processes that are important for maintaining cellular health and homeostasis. For instance, EEF1A1P5 has been shown to be involved in the regulation of cell division, which is critical for maintaining the growth and survival of cells. Additionally, EEF1A1P5 has been shown to be involved in the regulation of cell migration, which is critical for the development and maintenance of tissues and organs.

In conclusion, EEF1A1P5 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in the regulation of translation elongation and cellular processes that are important for maintaining cellular health and homeostasis makes it an attractive target for researchers to investigate further. Further studies are needed to determine the role of EEF1A1P5 in disease and to develop new strategies for the development of new therapies.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 5

Functions: This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis

The "EEF1A1P5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets